Tag: febrile neutropenia market size

Uncover key drivers, emerging technologies, and competitive movements shaping the febrile neutropenia market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Febrile Neutropenia Market be in 2030 compared with 2026?

The febrile neutropenia market size has demonstrated significant growth over recent years. This market is anticipated to increase from $11.28 billion in 2025 to $11.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The historical expansion can be attributed to several factors including a rise in cancer chemotherapy usage, an uptick in hospital admissions, the widespread availability of broad-spectrum antibiotics, heightened infection awareness, and the establishment of more oncology centers.

The febrile neutropenia market size is set to experience robust expansion in the upcoming years. It is projected to increase to $15.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This anticipated growth is influenced by advancements in targeted antimicrobial therapy, an expanding oncology patient demographic, more effective early infection detection, the growing utilization of G-CSFs, and the wider adoption of precision oncology care. Significant developments expected within this period include an increase in chemotherapy-induced neutropenia cases, the expanded use of empirical antibiotic therapy, a rising acceptance of supportive care treatments, the enhancement of hospital-based infection management, and improvements in diagnostic and monitoring technologies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

What Drivers Are Guiding Growth Patterns In The Febrile Neutropenia Market?

The expanding occurrence of cancer is projected to drive the expansion of the febrile neutropenia market in the future. Cancer is a multifaceted disease characterized by the unregulated proliferation of aberrant cells, capable of infiltrating adjacent tissues and metastasizing to various bodily regions. This increase in cancer cases stems from contributors such as an aging demographic, exposure to environmental and occupational hazards, genetic susceptibility, and hormonal and reproductive elements. Febrile neutropenia assists cancer patients by emphasizing the elevated danger of infections during chemotherapy, thus encouraging prompt intervention and specific therapies to avert critical complications, which in turn enhances patient results and allows for uninterrupted cancer treatment. For example, in 2024, the Canadian Cancer Society, a national cancer charity situated in Canada, reported that 32,100 individuals in Canada received a lung cancer diagnosis, representing 23.5% of total cancer-related fatalities. Significantly, instances of lung cancer among women climbed from 15,800 cases in 2023 to 17,300 cases in 2024. Consequently, the expanding prevalence of cancer is fueling the expansion of the febrile neutropenia market.

How Is The Febrile Neutropenia Market Divided Into Segments?

The febrile neutropenia market covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders

3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections

4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

Which Innovation Trends Are Advancing Developments Within The Febrile Neutropenia Market?

Leading companies active in the febrile neutropenia market are concentrating on developing innovative biosimilar drugs, such as prolonged-acting granulocyte-colony stimulating factor (G-CSF) fusion proteins, to attain a competitive advantage. These fusion G-CSFs are recombinant proteins that link G-CSF to an Fc fragment, allowing for sustained neutrophil stimulation over a chemotherapy cycle. As an illustration, in November 2024, Evive Biotech, a biopharmaceutical company headquartered in Singapore, launched in Germany a non-pegylated long-acting G-CSF designed for chemotherapy-induced neutropenia, which provides an extended half-life through an IgG2-Fc fusion and uses mammalian cell expression for human-like glycosylation. These subsequent-generation and biosimilar G-CSFs improve patient access and lessen dosing frequency, though they face regulatory intricacies and potential immunogenicity concerns.

Which Key Market Players Are Investing In Expansion And Innovation Within The Febrile Neutropenia Market?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Hospira Inc., Coherus BioSciences Inc., Gennova Biopharmaceuticals Limited, Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Zydus Cadila, Celltrion Inc., Samsung Bioepis Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Febrile Neutropenia Market?

North America was the largest region in the febrile neutropenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Febrile Neutropenia Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Browse Through More Reports Similar to the Global Febrile Neutropenia Market 2026, By The Business Research Company

Cephalosporin Market Report 2026

https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Lenalidomide Market Report 2026

https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Febrile Neutropenia Industry By 2029?

In recent years, the market size for febrile neutropenia has seen significant growth. We forecast further expansion from $10.6 billion in 2024 to $11.28 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.4%. This growth in the historic period can be linked to several factors. These include an increase in cancer cases, wider acceptance of chemotherapy, the expansion of personalized medicine, reduction in healthcare costs, and an increased prevalence of neutropenia.

In the forthcoming years, the febrile neutropenia market size is projected to demonstrate solid growth, escalating to $14.35 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. The increase in the forecast period is owing to factors such as the widening use of immunosuppressive medications, expanded R&D, favorable insurance reimbursement strategies, augmented investments, and a surge in instances of leukemia. The forecast period will also see key trends including advanced molecular diagnostics, the introduction of antimicrobial stewardship & de-escalation therapy, the use of immunotherapy & targeted treatments, risk stratification models, and progress in fungal biomarkers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

Which Growth Drivers Are Shaping The Febrile Neutropenia Market Outlook?

The surge in cancer occurrences is predicted to boost the progress of the febrile neutropenia market. Cancer is a set of complex diseases marked by unchecked growth of irregular cells capable of invading neighboring tissues and propagating to different body parts. The escalation in cancer cases is due to reasons such as escalating age of the population, exposure to environmental & occupational hazards, genetic susceptibilities, and hormonal & reproductive influencers. Febrile neutropenia assists those with cancer by underlining the increased susceptibility to infections during chemotherapy, stimulating early intervention and personalized treatments, and thereby preventing potentially fatal complications. This in turn enhances patient results and facilitates the punctual continuation of cancer treatment. For example, the American Cancer Society, a non-profit organization based in the U.S. that raises awareness about cancer, estimated in January 2022 that around 1.9 million new cancer cases and 609,360 cancer-linked deaths in the U.S. are anticipated, leading to about 1,670 deaths daily. As such, the growing prevalence of cancer instigates the expansion of the febrile neutropenia market.

How Is The Global Febrile Neutropenia Market Broken Down By Segment?

The febrile neutropeniamarket covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy; Targeted Antibiotic Therapy; Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia; Transplant-Related Neutropenia; Genetic Disorders

3) By Etiology: Gram-Negative Bacteria; Gram-Positive Bacteria; Fungal Infections; Viral Infections

4) By Diagnostic Methods: Blood Cultures; Imaging Tests; Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams; Glycopeptides; Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy; Antiviral Therapy; Gram-Positive Bacterial Therapy; Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs); Intravenous Fluids; Antipyretics And Pain Management

Which Trends Are Likely To Redefine Growth Paths In The Febrile Neutropenia Market?

Major companies in the febrile neutropenia market are developing biosimilar drugs to improve treatment accessibility. Biosimilars are biological products closely mirroring approved reference drugs in terms of structure, function, and efficacy, offering more affordable alternatives while adhering to stringent regulatory standards. For instance, in September 2022, Germany-based pharmaceutical firm Fresenius Kabi obtained FDA approval for its biosimilar Stimufend (pegfilgrastim-fpgk). The drug is intended for patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy, which can lead to febrile neutropenia, a condition marked by low white blood cell count and fever. The company plans to release Stimufend in a prefilled syringe format in early 2023 and is also working on an on-body injector for future use.

Who Are The Primary Market Leaders In The Febrile Neutropenia Market?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Febrile Neutropenia Market?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Browse Through More Reports Similar to the Global Febrile Neutropenia Market 2025, By The Business Research Company

Neutropenia Biologic Drug Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Chemotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Febrile Neutropenia Market?

The febrile neutropenia market has demonstrated robust growth over recent years. Its value is anticipated to rise from $10.6 billion in 2024 to $11.28 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.4%. This past growth can be ascribed to several factors, including the increasing occurrence of cancer, the wider embrace of chemotherapy, the development of personalized medicine, ongoing efforts to reduce healthcare costs, and the rising prevalence of neutropenia.

The febrile neutropenia market size is expected to undergo significant expansion over the next few years. It is projected to reach $14.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.2%. This growth during the forecast period can be attributed to several factors, including the increasing application of immunosuppressive drugs, heightened research and development initiatives, favorable reimbursement policies, growing investments, and a rise in leukemia cases. Noteworthy trends anticipated in this period encompass rapid molecular diagnostics, the adoption of antimicrobial stewardship and de-escalation therapy, the advancement of immunotherapy and targeted treatments, the development of risk stratification models, and improvements in fungal biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

What Are The Key Drivers Of Growth In The Febrile Neutropenia Market?

The growing occurrence of cancer is anticipated to propel the expansion of the febrile neutropenia market in the future. Cancer itself is a complex set of illnesses characterized by the unrestrained growth of abnormal cells, which can invade surrounding tissues and spread to other parts of the body. The increasing frequency of cancer cases arises from factors such as an aging demographic, environmental and occupational exposures, genetic predispositions, and hormonal and reproductive influences. Febrile neutropenia plays a crucial role in aiding cancer patients by underscoring the elevated risk of infections during chemotherapy, thereby prompting prompt intervention and focused treatments to prevent severe complications. This, in turn, improves patient outcomes and allows for the seamless continuation of cancer therapy. For example, in January 2022, the American Cancer Society, a US-based non-profit organization dedicated to cancer awareness, projected that in the US, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were expected, amounting to about 1,670 deaths per day. Hence, the rising prevalence of cancer is a key driver for the growth of the febrile neutropenia market.

What Are The Major Segment Types Covered In The Febrile Neutropenia Market?

The febrile neutropeniamarket covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy; Targeted Antibiotic Therapy; Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia; Transplant-Related Neutropenia; Genetic Disorders

3) By Etiology: Gram-Negative Bacteria; Gram-Positive Bacteria; Fungal Infections; Viral Infections

4) By Diagnostic Methods: Blood Cultures; Imaging Tests; Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams; Glycopeptides; Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy; Antiviral Therapy; Gram-Positive Bacterial Therapy; Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs); Intravenous Fluids; Antipyretics And Pain Management

How Are Emerging Market Trends Shaping The Febrile Neutropenia Industry Landscape?

Companies operating within the febrile neutropenia market are prioritizing the creation of advanced biosimilar drugs to improve the availability of treatment options. Biosimilar drugs are biological products that bear a strong resemblance to approved reference drugs concerning their structure, function, and effectiveness. They provide an economical alternative to original biologics, thereby enhancing patient access while adhering to stringent regulatory benchmarks. For example, in September 2022, Fresenius Kabi, a pharmaceutical company based in Germany, secured U.S. Food and Drug Administration (FDA) approval for its biosimilar Stimufend (pegfilgrastim-fpgk). This authorization enables the use of Stimufend in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy, a treatment that can result in febrile neutropenia—a severe condition defined by a reduced white blood cell count and fever. The company aims to introduce Stimufend in a prefilled syringe format in early 2023 and is additionally developing an on-body injector for future application.

Which Major Industry Participants Are Leading The Febrile Neutropenia Market Growth?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Regional Markets Are Contributing Most To The Febrile Neutropenia Industry Expansion?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Febrile Neutropenia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Browse Through More Reports Similar to the Global Febrile Neutropenia Market 2025, By The Business Research Company

Neutropenia Biologic Drug Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Chemotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Febrile Neutropenia Market Size Shifted, And What Is the Outlook Through 2034?

The market size for febrile neutropenia has seen robust expansion in the last few years. With an uptick from $10.6 billion in 2024 to an estimated $11.28 billion in 2025, the market is projected to experience a compound annual growth rate (CAGR) of 6.4%. The surge observed in the historical timeframe can be ascribed to several factors like the increasing occurrence of cancer, wider acceptance of chemotherapy, growth of personalized medicine, reduction in healthcare expenses, and increased cases of neutropenia.

The market size for febrile neutropenia is projected to experience substantial growth in the upcoming years, increasing to$14.35 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. This growth within the forecast period can be credited to the escalating utilization of immunosuppressive drugs, significant R&D advancements, favorable rebate policies, augmented investments, and a surge in leukemia occurrences. The key trends anticipated during the forecast period encompass accelerated molecular diagnostics, acceptance of antimicrobial stewardship along with de-escalation therapies, immunotherapy & targeted treatments, the development of risk stratification models, and evolution in fungal biomarkers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Febrile Neutropenia Market?

The growth of the febrile neutropenia market is anticipated to be fueled by the escalating incidence of cancer. This intricate group of diseases, defined by the unchecked proliferation of anomalous cells that can encroach on nearby tissues and metastasize to other body parts, is observing an upward trend. Causes of rising cancer occurrence include an aging population, environmental and occupational exposure, genetic susceptibility, as well as reproductive and hormonal factors. For cancer patients, febrile neutropenia is critical in spotlighting the increased infection risk during chemotherapy, which necessitates early measures and customized treatments that help avert severe complications. This, in turn improves patient outcomes and allows for ongoing cancer treatment in a timely manner. For instance, the American Cancer Society, a non-profit organization based in the US dedicated to cancer awareness, estimated in January 2022 that around 1.9 million new cancer cases and about 609,360 cancer-related fatalities are predicted in the US, resulting in nearly 1,670 deaths each day. Hence, the surging incidence of cancer is propelling the febrile neutropenia market’s expansion.

Which Primary Segments of the Febrile Neutropenia Market Are Driving Growth and Industry Transformations?

The febrile neutropeniamarket covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy; Targeted Antibiotic Therapy; Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia; Transplant-Related Neutropenia; Genetic Disorders

3) By Etiology: Gram-Negative Bacteria; Gram-Positive Bacteria; Fungal Infections; Viral Infections

4) By Diagnostic Methods: Blood Cultures; Imaging Tests; Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams; Glycopeptides; Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy; Antiviral Therapy; Gram-Positive Bacterial Therapy; Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs); Intravenous Fluids; Antipyretics And Pain Management

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Febrile Neutropenia Market?# Market?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Febrile Neutropenia Market?

Leading businesses in the febrile neutropenia market are concentrating on the creation of advanced biosimilar medicines to improve treatment availability. Biosimilar medicines, which are biologics closely mirroring approved reference drugs in form, function, and efficiency, provide affordable alternatives to original biologics, enhance patient access, and comply with strict regulatory guidelines. Take, for example, Fresenius Kabi, a pharmaceutical company from Germany, which acquired approval from the U.S. Food and Drug Administration (FDA) in September 2022 for its biosimilar, Stimufend (pegfilgrastim-fpgk). This approval enables Stimufend to be administered for patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy leading to febrile neutropenia, a severe condition marked by fever and low count of white blood cells. The company aims to introduce Stimufend in a pre-filled syringe design in early 2023 and is also working on an on-body injector for future application.

View the full report here:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

What Parameters Are Used to Define the Febrile Neutropenia Market?

Febrile neutropenia is a medical condition characterized by a fever (temperature of 100.4°F or higher) and a low number of neutrophils, which are a type of white blood cell essential for fighting infections. This condition is often seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more vulnerable to infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Febrile Neutropenia Market from 2024 to 2025?

The market size of febrile neutropenia has seen robust growth in the past few years. There is an expected rise from $10.60 billion in 2024 to $11.31 billion in 2025, projecting a compound annual growth rate (CAGR) of 6.7%. This growth during the historical period is due to several factors such as an increase in cancer cases, the widespread use of chemotherapy, the proliferation of personalized medicine, a decrease in healthcare expenses, and a rise in instances of neutropenia.

What Is the Projected Market Size of the Febrile Neutropenia Market?

The market size for febrile neutropenia is projected to experience significant expansion in the coming years. An expected growth of up to $14.48 billion is forecasted by 2029, marking a compound annual growth rate (CAGR) of 6.4%. The anticipated growth during this prediction period is a result of factors such as the increased usage of immunosuppressive drugs, intensifying research and development, positive reimbursement policies, elevated investment levels, and a heightened number of leukemia cases. The forecast period also indicates key trends, including quick molecular diagnostics, the application of antimicrobial stewardship and de-escalation therapy, the use of immunotherapy & targeted treatments, risk stratification models, and progress in fungal biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

Who are the Major Competitors in the Febrile Neutropenia Market Outlook?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech

What Is Fueling Growth in the Febrile Neutropenia Market?

Progress in the febrile neutropenia market is anticipated to be spurred on by the rising incidence of cancer. Cancer is a multifaceted set of diseases, identifiable by unregulated cell growth that can invade local tissues and metastasize. The escalating prevalence of cancer can be attributed to factors such as the aging demographic, environmental and occupational risk exposures, genetic tendencies, as well as hormonal and reproductive factors. Febrile neutropenia aids cancer patients by underscoring the increased risk of infections during chemotherapy. This facilitates prompt interventions and specialized treatment to avert critical complications, thus improving patient prognosis and enabling cancer treatments to continue without delay. For instance, the American Cancer Society, a non-profit cancer awareness organization in the US, reported in January 2022, that the country is expected to register approximately 1.9 million new cancer cases and 609,360 cancer-related fatalities, averaging around 1,670 deaths daily. As a result, the growing prevalence of cancer is fueling the expansion of the febrile neutropenia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Which Febrile Neutropenia Market Segments Are Growing the Fastest?

The febrile neutropenia market covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders

3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections

4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

Which Industry Trends Are Shaping the Future of the Febrile Neutropenia Market?

Large corporations within the febrile neutropenia sector are directing their efforts towards the creation of state-of-the-art biosimilar drugs, aimed at improving the availability of treatments. Biosimilars are biologic medications that are created to replicate the approved reference drugs in terms of their structure, function, and effectiveness. As lower-cost options to the original biologics, these drugs enhance patient access while also meeting stringent regulatory requirements. For example, in September 2022, the U.S. FDA approved the biosimilar Stimufend (pegfilgrastim-fpgk), developed by Fresenius Kabi, a pharmaceutical firm based in Germany. This approval greenlights the use of Stimufend for patients suffering from non-myeloid malignant conditions who are undergoing myelosuppressive chemotherapy, a possible cause of febrile neutropenia, a severe condition marked by an abnormally low count of white blood cells and fever. By early 2023, Fresenius Kabi plans to introduce Stimufend in a prefilled syringe form, with plans for an on-body injector currently in the pipeline.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Countries Are Leading the Febrile Neutropenia Market?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187

This Report Delivers Insight On:

1. How big is the febrile neutropenia market, and how is it changing globally?

2. Who are the major companies in the febrile neutropenia market, and how are they performing?

3. What are the key opportunities and risks in the febrile neutropenia market right now?

4. Which products or customer segments are growing the most in the febrile neutropenia market?

5. What factors are helping or slowing down the growth of the febrile neutropenia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Are the Projected Market Size and Growth Rates for the Febrile Neutropenia Market From 2025 To 2029?

The market size for febrile neutropenia has seen a significant increase in the past few years. The market is projected to expand from $10.60 billion in 2024 to $11.31 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 6.7%. Factors like the escalating caseload of cancer, increased utilization of chemotherapy, the popularity of personalized medicine, decreasing costs of healthcare, and the rising incidences of neutropenia have contributed to the growth observed in the historic period.

In the coming years, the market size for febrile neutropenia is predicted to witness substantial growth, rising to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be credited to an increased usage of immunosuppressive medications, elevation in R&D activities, favorable reimbursement policies, greater investments, and a surge in leukemia instances. Major trends throughout the forecast period encompass swift molecular diagnostics, uptake of antimicrobial stewardship & de-escalation therapy, immunotherapy & targeted treatments, risk stratification models, as well as progress in fungal biomarkers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Febrile Neutropenia Market?

The surging occurrence of cancer is predicted to fuel the expansion of the febrile neutropenia market in the future. Cancer refers to a range of diseases defined by the unchecked multiplication of abnormal cells that have the potential to infiltrate neighboring tissues and metastasize to other body parts. The escalating incidence of cancer can be traced back to reasons like aging population, environmental and work-related exposure, genetic susceptibility, and hormonal and reproductive contributors. Febrile neutropenia aids cancer patients by underscoring the escalated risk of infections during chemotherapy. This alerts early interference and customized treatments to avert critical complications, hence enhancing patient results and facilitating prompt continuation of cancer treatment. For instance, the American Cancer Society, a US-based non-profit organization promoting cancer awareness, anticipated in January 2022 that the US could witness approximately 1.9 million fresh cancer cases and around 609,360 cancer-associated deaths, culminating in approximately 1,670 deaths daily. Consequently, the escalating occurrence of cancer is spurring the growth of the febrile neutropenia market.

Which Key Market Segments Comprise the Febrile Neutropenia Market and Drive Its Revenue Growth?

The febrile neutropenia market covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders

3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections

4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Which Areas Are Leading Regions in the Febrile Neutropenia Market Expansion Across the Globe?

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theFebrile Neutropenia Market Over the Coming Years?

Leading firms in the febrile neutropenia market are prioritizing the development of advanced biosimilar drugs to increase ease of treatment. Biosimilar medicines are biological agents that exhibit a high degree of similarity to previously approved reference drugs in terms of structure, function, and effectiveness. These bio-mimicry offer cost-efficient replacements for original biologics, widening patient reach and fulfilling rigorous regulatory requirements. Case in point, Fresenius Kabi, a pharmaceutical corporation based in Germany, garnered approval for its biosimilar, Stimufend (pegfilgrastim-fpgk), from the U.S. Food and Drug Administration (FDA) in September 2022. This authorization expands the usage of Stimufend to patients with non-myeloid cancers undergoing myelosuppressive chemotherapy that could result in febrile neutropenia, an extreme medical circumstance marked by a reduction in white blood cells and feverish symptoms. The firm anticipates to introduce Stimufend in a preloaded injection format in early 2023 and is concurrently exploring the development of an on-body injector for future utilization.

View the full report here:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

How Is the Febrile Neutropenia Market Conceptually Defined?

Febrile neutropenia is a medical condition characterized by a fever (temperature of 100.4°F or higher) and a low number of neutrophils, which are a type of white blood cell essential for fighting infections. This condition is often seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more vulnerable to infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model